Thymosin α-1 vs Thymalin.

Thymosin alpha-1 (Tα1, international nonproprietary name thymalfasin; brand name Zadaxin) is a synthetic 28-amino-acid acetylated peptide identical to a naturally occurring fragment derived from prothymosin alpha, a protein produced in the thymus. It belongs to the thymosin family of thymic-derived peptides and is one of the most clinically studied immunomodulatory peptides, marketed as a prescription immune modulator in numerous countries outside the United States.

Thymalin is a peptide preparation originally isolated as a polypeptide fraction from calf thymus gland, developed by Vladimir Khavinson's group in the Soviet Union and Russia. It belongs to the family of so-called peptide bioregulators and is associated with short peptide sequences (notably Lys-Glu and Glu-Trp) proposed as its active elements. It is positioned as a thymic immunomodulator intended to counter age-related decline of the thymus and T-cell immunity. In Russia it is a registered pharmaceutical; elsewhere it is treated as a research compound.

Tα1 is an immune modulator rather than a simple immune stimulant: it acts largely through Toll-like receptors, principally TLR2 and TLR9, on dendritic cells, monocytes/macrophages, and other antigen-presenting cells. Downstream MyD88-dependent signaling promotes dendritic cell maturation, biases naive T cells toward Th1 differentiation, augments natural killer cell and cytotoxic T-cell activity, and can modulate regulatory pathways including indoleamine 2,3-dioxygenase. In settings of immune exhaustion or sepsis-associated immunoparalysis, the proposed benefit is restoration of T-lymphocyte numbers and function (e.g., raising depleted CD4+/CD8+ counts and reducing markers of T-cell exhaustion) rather than broad immune activation.

Thymalin is proposed to act as an immune bioregulator that supports differentiation and function of T-lymphocytes and helps normalize the T-helper/T-suppressor balance. The Khavinson group hypothesizes that its constituent short peptides can enter cells and interact with DNA and chromatin to modulate tissue-specific gene expression, nudging an aged or dysregulated immune system toward a more youthful pattern. Some experimental work reports effects on the differentiation of hematopoietic stem cells. These proposed mechanisms are largely derived from the originating laboratory's own animal and cell studies rather than from independent mechanistic confirmation.

Human evidence is most developed in chronic hepatitis B and as an adjunct in sepsis, but is mixed and often comes from China-based studies of variable quality. The largest dedicated sepsis trial, ETASS (Wu et al., Critical Care 2013, a multicenter single-blind RCT of 361 patients with severe sepsis), found a reduction in 28-day all-cause mortality that did not reach statistical significance, so its primary endpoint was formally negative; subsequent systematic reviews (e.g., Liu et al., BMC Infect Dis 2016) noted possible mortality benefit but flagged small sample sizes, heterogeneity, and risk of bias. In COVID-19, the widely cited Liu et al. (Clin Infect Dis 2020) report associating Tα1 with lower mortality was a retrospective review of only 76 severe cases, not a randomized trial, and cannot establish efficacy. For hepatitis B, meta-analyses (e.g., entecavir plus Tα1 in HBV-related cirrhosis, BMC Gastroenterol 2020) suggest possible adjunctive benefit on virologic and immune endpoints but again rest on heterogeneous trials; high-quality Western regulatory trials have not confirmed a clear benefit. Much of the broader "immune-restoring" and anti-cancer rationale remains preclinical or mechanistic.

The published evidence for thymalin comes overwhelmingly from Vladimir Khavinson and collaborators, appearing mainly in Russian-language journals and outlets such as Bulletin of Experimental Biology and Medicine and Neuro Endocrinology Letters. The most cited human data is a multi-year, non-blinded geroprotection program in elderly subjects reporting improved immune parameters and lower mortality versus controls, but it was not a modern blinded, independently replicated randomized controlled trial. That program was reported retrospectively across several summary papers rather than as a single prespecified protocol, and the published accounts do not describe randomization procedure, allocation concealment, blinded outcome assessment, prespecified primary endpoints, or independent data monitoring. Companion reviews such as the 2002 Neuro Endocrinology Letters paper on peptides and ageing present thymalin alongside epithalamin as part of a single geroprotective program, so the human results for the two preparations are frequently reported together rather than separately. More recent papers describe effects on hematopoietic stem cell differentiation and gene expression, again largely from the same group and largely in cell culture, including work on peptide regulation of immune and inflammatory pathways in spleen tissue and in monocyte and macrophage cell lines. Independent Western replication in rigorous RCTs is essentially absent, so the evidence base should be read as preliminary and heavily single-source. Readers should weigh the near-total reliance on one research group when interpreting any claims. The contrast with Cerebrolysin is a useful calibration: Cerebrolysin, another animal-tissue peptide preparation, has accumulated enough independent randomized trials to support two Cochrane systematic reviews, and those reviews still reached cautious and largely non-endorsing conclusions. Thymalin has not reached even that level of external scrutiny, and it shares this position with the other bioregulators in the same tradition, notably vilon, cortexin and epitalon. What is not known is substantial: there is no published modern toxicology package, no pharmacokinetic characterization of the fraction in humans, no batch-to-batch potency standard visible in the international literature, and no registration-quality trial outside Russia.

Across decades of clinical use as thymalfasin, Tα1 has generally been reported as well tolerated, with injection-site reactions among the more commonly noted effects; it is a peptide given by injection in studied settings. Because its action is immunomodulatory, theoretical and context-dependent concerns include effects in autoimmune disease, transplant recipients, or other immune-sensitive populations, and immunogenicity is one reason regulators have scrutinized compounded versions. Importantly, much safety data comes from regulated pharmaceutical product used under medical supervision; the purity, identity, and safety of research-grade or compounded "gray market" material are not assured, and long-term safety outside approved indications is not well characterized.

Reported human and animal experience describes thymalin as generally well tolerated in the contexts studied, with few documented serious adverse effects in the originating literature. However, because independent long-term safety data and modern regulatory review outside Russia are lacking, its safety profile in broad populations is not well established, and the absence of reported harms in single-group publications is weak evidence of safety rather than positive evidence of it. As a parenteral preparation derived from calf tissue, it carries the generic concerns that apply to all animal-sourced injectable biologicals: hypersensitivity and anaphylactoid reactions to foreign protein, immunogenicity on repeated exposure, injection-site reactions, and dependence on the source herd and the purification process for freedom from adventitious agents. An agent proposed to modulate T-cell function also raises a theoretical question in autoimmune disease and in people taking immunosuppressive therapy, and that question has not been studied. Product purity and identity are also uncertain for material obtained outside regulated pharmaceutical channels, where lyophilized vials sold as research chemicals carry no verified sterility, endotoxin or content assay. A genuine safety evaluation would require what the existing literature does not provide: prospective adverse-event capture, immunological and hepatic and renal laboratory monitoring, anti-drug antibody testing, and follow-up long enough to detect delayed effects. This is educational information only and not medical or dosing advice.

Thymalfasin (Zadaxin) is approved and marketed as a prescription drug in roughly 30-plus countries (including China, Italy, and parts of Asia, Latin America, and the Middle East), chiefly for chronic hepatitis B and as an immune adjunct, but it is NOT approved by the US FDA or centrally by the EMA; in the US it has held orphan-drug designations and been studied investigationally. In US compounding, FDA placed thymosin alpha-1 in Category 2 of the interim 503A bulk substances list in 2023 (citing safety/data concerns), and in 2024 it was removed from Category 2 after its nomination was withdrawn, leaving it without a clear compounding pathway.

Thymalin is registered and used as an approved medicine in Russia, where it has a long clinical history. It is not approved by the US FDA or the European Medicines Agency and has no approved indication in the US, where it would be considered an unapproved research substance. It is not a dietary supplement.